Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Change in Accured Expenses (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Change in Accured Expenses data on record, last reported at -$949139.0 in Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 48.8% year-over-year to -$949139.0; the TTM value through Sep 2025 reached $258582.0, up 137.24%, while the annual FY2024 figure was $274889.0, 139.63% up from the prior year.
  • Change in Accured Expenses reached -$949139.0 in Q3 2025 per GANX's latest filing, down from $151651.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.7 million in Q1 2022 and bottomed at -$1.9 million in Q3 2024.
  • Average Change in Accured Expenses over 5 years is $67072.4, with a median of $3456.0 recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 50338.17% in 2022, then crashed 3920.98% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at -$589191.0 in 2021, then tumbled by 39.6% to -$822482.0 in 2022, then decreased by 24.9% to -$1.0 million in 2023, then skyrocketed by 94.35% to -$58070.0 in 2024, then plummeted by 1534.47% to -$949139.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$949139.0 in Q3 2025, $151651.0 in Q2 2025, and $1.1 million in Q1 2025.